Human recombinant interleukin-12 and circulating CD4+ and CD8+ T cells in patients with mild allergic asthma
Journal of Organ Dysfunction, ISSN: 1747-1060, Vol: 4, Issue: 2, Page: 77-84
2008
- 4Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures4
- Readers4
Article Description
Objective. Recombinant human (rHu) interleukin (IL)-12 has been shown to reduce levels of blood and sputum eosinophils in patients with mild allergic asthma in a randomized controlled study. The aim of the study was to investigate whether four escalating weekly subcutaneous injections of rHuIL-12 in allergic asthmatic patients could induce changes in the intracellular cytokine profile of the circulating blood CD4+ and CD8+ T cells. Material and methods. Purified CD4+ and CD8+ T cells from peripheral blood mononuclear cells of 11 patients (six received rHuIL-12 and five received placebo) were collected before and after 4 weeks of treatment, and cultured in the presence of phorbol myristate acetate for 4 days, with or without the addition of IL-12 in vitro. Expression of various intracellular cytokines was determined using flow cytometry following treatment with brefeldin-A and saponin. Results. Compared to placebo, the proportions of peripheral blood interferon-γ-, IL-4-, IL-2- or IL-10-producing CD4+ or CD8+ T cells were not significantly changed following rHuIL-12 treatment. Conclusion. Four weekly treatments with rHuIL-12 do not produce peripheral blood T-cell changes detectable with our experimental setting and methodology. © 2008 Taylor & Francis.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know